Opening and welcome remarks (ID 1811)
Upfront strategy: Third-generation EGFR TKI as first-line therapy (ID 1812)
Sequencing strategy: First- or second-generation TKI followed by third-generation EGFR TKI (ID 1813)
Combination strategy: EGFR TKI and chemotherapy/anti-angiogenic combinations (ID 1814)
Expert panel interactive forum (ID 1867)
Closing remarks (ID 1815)